RegulatoryBusinessLine
USFDA issues 7 observations to NATCO Pharma
Negative-678 sources
GreyOak summary
NATCO Pharma Limited received seven observations from the USFDA following an inspection of its Hyderabad manufacturing facility. The regulator cited conditions that may constitute violations of laws. The company describes the issues as procedural and is confident in addressing them within stipulated timelines.
What it affects
- Natco PharmaNATCOPHARMNegative -67
Received 7 USFDA observations on facility.Rolling sentiment Negative -38
Source
Reported by BusinessLine
- Business Today
- BusinessLine
- Economic Times
- Economic Times
- Economic Times
- CNBC-TV18
- Business Standard
- BusinessLine
More Natco Pharma news
- Natco Pharma receives EIR from US FDA for Visakhapatnam plantCNBC-TV18 · Company update ·
- Buy Natco Pharma: target of Rs 1065: ICICI SecuritiesMoneycontrol · Company update ·
- Natco Pharma shares rally 9% despite weak Q2 resultsNDTV Profit · Results ·